Legal Disclaimer

The content and information provided within this site is for informational and educational purposes only. Consult a doctor before pursuing any form of therapy, including Hyperbaric Oxygen Therapy. The Information provided within this site is not to be considered Medical Advice. In Full Support of the F.D.A., Hyperbaric Oxygen Therapy is considered Investigational, Experimental, or Off Label.

Please consult with your Treating Medical Physician

~UPDATE 26TH MAY 2003~

Improvement in Autistic Male 17- years -old
Patient was being treated for Autism and Seizures
Improvement in social skills, Grades and Seizures reduced after 50 Hyperbaric Oxygen treatments from several daily to once weekly.
Improvement in Brain SPECT scan are visible one year later.

Reproduced with Permission.

What is a SPECT Brain Scan?

Single Photon-Emission Computed Tomography uses the injection of a radioisotope that is carried in the blood to the tissues. The isotope passes into the tissue and the radiation can be detected using a gamma camera. The greater the blood flow the more is taken up by the tissue. The resulting computed image displays the concentration as a color and the convention for the image is that white is the highest level followed by red, yellow, green, blue etc.

S.P.E.C.T. Brain Scans is a new, advanced diagnostic nuclear medical Imaging procedure that provides “ cross sections of the brain Images” Unlike MRI and CAT Scans which only depict anatomy, S.P.E.C.T. Brain Scans shows actual brain blood flow function.

S.P.E.C.T. Brain Scanning pinpoints the position of recoverable brain cells, (referred to as Sleeping cells or Idling neurons or Ischemic Penumbra).

We refer our Patients to Dr Uszler MD of UCLA, whom we introduced Hyperbaric Oxygen Therapy to in 1991 with following Patients.

SPECT brain Scans before and after one treatment.

SPECT Brain Scans after 28 treatments of Hyperbaric Oxygen Therapy

Mealey's Daubert Report
March 1998

SPECT Scan Evidence Passes Daubert Test, Massachusetts Judge Rules


A trial judge rejected defense arguments made in a five-day Daubert hearing and allowed the testimony of a plaintiff's expert in a toxic encephalopathy (TSE) case (Carol Rowe Rhilinger v. Leslie G. Jancics, et al., No. 93-2223, Mass. Super., Norfolk Co.).

Specifically, Norfolk County Superior Court Judge Julian T. Houston held a jury can consider the results of a Single Photo Emission Computed Tomography (SPECT) test. The court also approved of plaintiff's expert's use of a "differential diagnosis."

Carol Rowe Rhilinger allegedly contracted TSE from exposure to chemicals stored in the basement of the building where she lived. She asserted the illegal storage of the chemicals resulted in leakage and a migration of fumes to her apartment, eventually causing her brain damage.

The defendants argued that use of a SPECT brain scan to diagnose the plaintiff's TSE was not supported by valid scientific evidence, nor has it been empirically tested or studied or is it generally accepted as a diagnostic tool for TSE.

The court noted that SPECT technology has been used by the medical community for at least 15 years.

"There is no dispute that SPECT scans show abnormalities in brain function," said the court. "Neither is there a dispute that SPECT scans cannot conclusively establish the existence or non-existence of TSE in a patient. Plaintiff's experts do not opine that the SPECT scan does, in fact, establish the diagnosis. They merely assert that is one of a constellation of diagnostic tools which they used and considered consistent with their conclusion that Rhilinger suffers from TSE."

The judge also added that there was no dispute that SPECT technology is relevant to prove or disprove the other possible explanations for the plaintiff's condition.

The judge held that SPECT is "scientifically reliable" in such a toxic tort case.

Defense Expert

In a separate ruling, the court said information it had ordered produced by Environmental Sensitivities Research Inc. (ESRI) regarding the proposed testimony of defense witness Dr. Ronald Gots was relevant to the doctor's potential bias as a witness.

The court noted ESRI "refused to comply fully with the order because of its fear that information regarding membership and funding would be disclosed" to parties outside the present case.

During the Daubert hearing, the court said it would not consider Dr. Gots' affidavits unless compliance with the prior court order regarding information about the doctor's affiliation with ESRI was produced.

While he was not precluded from testifying under Daubert, Dr. Gots is presently barred from appearing at the trial until ESRI complies with the court order.

Rhilinger is represented by the Law Offices of Robert C. Autieri of North Andover, Mass. Defense counsel include Mark Granger of Morrison, Mahoney & Miller of Boston and Mark Furcolo and Joni Katz Mackler of Burns & Levinson of Boston.

Opinion available doc# 15-980130-105

Contact Mealey Publications Inc. at 1-800-MEALEYS:

Air embolism: diagnosis with single-photon emission tomography and successful hyperbaric oxygen therapy.

Droghetti L, Giganti M, Memmo A, Zatelli R.

Department of Anaesthesia and Intensive Care Medicine, S. Anna Hospital, I-44100 Ferrara, Italy.

Venous air embolism may occur when the surgical field is above the level of the heart. We present a case of venous air embolism in a patient undergoing percutaneous nephrolithotripsy in the prone position and presenting with blindness and neurological deficits 8 h later. The clinical diagnosis of paradoxical air embolism was confirmed by early single-photon emission tomography (SPET), whereas magnetic resonance imaging including diffusion-weighted imaging (DW-MRI) was diagnostic only 30 h later. Hyperbaric oxygen therapy was successful. In this case, early DW-MRI scan was inconclusive, but a SPECT study of the brain appeared to be useful in confirming the clinical diagnosis. Early hyperbaric oxygen was demonstrated to be a successful therapy.

The possible effect of clinical recovery on regional cerebral blood flow deficits in Fibromyalgia: a prospective study with semi quantitative Brain SPECT Scan.

Adiguzel O, Kaptanoglu E, Turgut B, Nacitarhan V.

Department of Rheumatology, Cumhuriyet University, Sivas, Turkey.

OBJECTIVES: Regional deficits in cerebral blood flow have been reported in a few studies of Fibromyalgia; however, there is no information on the effects of treatment and clinical recovery on these abnormalities. We evaluated the effects of amitriptyline treatment and consequent clinical recovery on cerebral blood flow changes in Fibromyalgia. METHODS: We assessed cerebral blood flow with a semi quantitative functional brain mapping technique of single-photon emission computed tomography in 14 patients with primary Fibromyalgia before and after 3 months of amitriptyline treatment. Patients were followed by visual analog scale, tender point count, and Beck Depression Inventory for clinical improvement. RESULTS: There was statistically significant improvement in visual analog scale and tender point count after treatment. Beck Depression Inventory did not change significantly. Statistically significant blood flow increase in bilateral hemithalami and basal ganglia and decrease in bilateral temporal, left temporo-occipital, and right occipital lobes were observed on single-photon emission computed tomography after treatment. CONCLUSIONS: We speculate that these findings could indicate that deficits in cerebral blood flow in Fibromyalgia improve parallel to clinical recovery.

PMID: 15301122 [PubMed - indexed for MEDLINE]